InvestorsHub Logo
Followers 0
Posts 29
Boards Moderated 0
Alias Born 05/07/2019

Re: None

Wednesday, 09/02/2020 3:42:18 PM

Wednesday, September 02, 2020 3:42:18 PM

Post# of 44690
Emailed the contacts on the last trial press release today.

Last time the trial news was released these were the contacts on the news release so I emailed them to see if either they going to release a press release or something.

From: dan sanSent: Wednesday, September 2, 2020 7:34 PMTo: ceo@neurorxpharma.com <ceo@neurorxpharma.com> <ceo@neurorxpharma.com>; david.schull@russopartnersllc.com <david.schull@russopartnersllc.com> <david.schull@russopartnersllc.com>; bkorb@troutgroup.com <bkorb@troutgroup.com> <bkorb@troutgroup.com>; Neurorx@mc-services.eu; yves.sagot@relieftherapeutics.com <yves.sagot@relieftherapeutics.com>; yves.sagot@relieftherapeutics.com <yves.sagot@relieftherapeutics.com>Subject: Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS

Good day,



Excuse me if I’m contacting the wrong individual, but I’m an investor of Relief Therapeutics Holdings and while searching through the clinical website I noticed this update.



https://clinicaltrials.gov/ct2/show/NCT04536350

Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS - Full Text View - ClinicalTrials.gov
Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS - Full Text View.
clinicaltrials.gov



Is this a new part of the trials and if so why haven’t this new been released to the public media yet?



Sincerely,



Dan San